From BioDlink Jan 15 2026 Research-backed strategy produces highly homogeneous antibody-drug conjugates (gsADCs) with consistent DAR and tumor suppression lasting over 50 days after a single dose A new white paper from BioDlink, From Complexity to Consistency: How CDMOs Can Unlock One-Step, High-Yield and Homogeneous ADC Manufacturing for Next-Gen Oncology , reveals an advancement in antibody-drug conjugate (ADC) manufacturing - achieving over 95% conjugation yield in under one hour using a one-